These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16227950)

  • 1. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease.
    Seibyl J; Jennings D; Tabamo R; Marek K
    Minerva Med; 2005 Oct; 96(5):353-64. PubMed ID: 16227950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research.
    Seibyl J; Jennings D; Tabamo R; Marek K
    Q J Nucl Med Mol Imaging; 2005 Jun; 49(2):215-21. PubMed ID: 16010256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional brain imaging in the differential diagnosis of Parkinson's disease.
    Piccini P; Whone A
    Lancet Neurol; 2004 May; 3(5):284-90. PubMed ID: 15099543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging.
    Huang WS; Lin SZ; Lin JC; Wey SP; Ting G; Liu RS
    J Nucl Med; 2001 Sep; 42(9):1303-8. PubMed ID: 11535717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.
    Booij J; Knol RJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S425-8. PubMed ID: 18267276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment.
    Derejko M; Sławek J; Wieczorek D; Brockhuis B; Dubaniewicz M; Lass P
    Nucl Med Commun; 2006 Dec; 27(12):945-51. PubMed ID: 17088679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-synuclein imaging: a critical need for Parkinson's disease research.
    Eberling JL; Dave KD; Frasier MA
    J Parkinsons Dis; 2013; 3(4):565-7. PubMed ID: 24192754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders.
    Seibyl JP
    Semin Nucl Med; 2008 Jul; 38(4):274-86. PubMed ID: 18514083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Eckert T; Tang C; Eidelberg D
    Lancet Neurol; 2007 Oct; 6(10):926-32. PubMed ID: 17884682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview: Radiotracers and nano-radiopharmaceuticals for diagnosis of Parkinson's disease.
    Ozolmez N; Silindir-Gunay M; Volkan-Salanci B
    Appl Radiat Isot; 2024 Jan; 203():111110. PubMed ID: 37989065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging in Parkinson's Disease.
    Politis M; Pagano G; Niccolini F
    Int Rev Neurobiol; 2017; 132():233-274. PubMed ID: 28554409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.
    Conrado DJ; Nicholas T; Tsai K; Macha S; Sinha V; Stone J; Corrigan B; Bani M; Muglia P; Watson IA; Kern VD; Sheveleva E; Marek K; Stephenson DT; Romero K;
    Clin Transl Sci; 2018 Jan; 11(1):63-70. PubMed ID: 28749580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of 123I-metaiodobenzylguanidine scintigraphy/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes.
    Jost WH; Del Tredici K; Landvogt C; Braune S
    Neurodegener Dis; 2010; 7(5):341-7. PubMed ID: 20616568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroimaging and transcranial ultrasonography in Parkinson's disease.
    Mehta SH; Morgan JC; Sethi KD
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):297-303. PubMed ID: 18590613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging the Nonmotor Symptoms in Parkinson's Disease.
    Yousaf T; Wilson H; Politis M
    Int Rev Neurobiol; 2017; 133():179-257. PubMed ID: 28802921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic use of functional imaging in Parkinson's disease and related disorders].
    Hanakawa T; Kawasaki K; Hashikawa K; Fukuyama H
    Nihon Rinsho; 2004 Sep; 62(9):1733-8. PubMed ID: 15462394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is DaTSCAN really needed for accurate Parkinson's disease diagnosis?
    de la Fuente-Fernández R
    Expert Rev Neurother; 2012 Dec; 12(12):1375-7. PubMed ID: 23237344
    [No Abstract]   [Full Text] [Related]  

  • 20. Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease.
    Winogrodzka A; Booij J; Wolters ECh
    Parkinsonism Relat Disord; 2005 Dec; 11(8):475-84. PubMed ID: 16257254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.